GlassScriptPhysician profile
Darlys Roy Hofer
NPI 1164470076
$1,058.03
in general payments reported to CMS, 2019-2025
26 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2021: $174 · 2022: $262 · 2023: $116 · 2024: $83.64 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.88 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $108.23 | 2019 | |
| Pfizer INC. | $99.43 | 2021-2025 | |
| Janssen Biotech, INC. | $82.86 | 2021-2025 | Erleada |
| Sumitomo Pharma America, INC. | $74.96 | 2024-2025 | Orgovyx |
| Astellas Pharma US INC | $57.81 | 2019-2023 | Myrbetriq |
| Boston Scientific Corporation | $54.82 | 2019-2023 | Lumenis Pulse 120h |
| Teleflex LLC | $49.49 | 2023 | Urolift |
| Tactile Systems Technology INC | $49.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.81 | 2022-2025 | |
| C. R. Bard, INC. & Subsidiaries | $37.31 | 2023-2025 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire, Bard Urinary Drainage Bag |
| Endo Pharmaceuticals INC. | $31.39 | 2022-2023 | Xiaflex, Aveed |
| Kci USA, INC. | $19.64 | 2022 | |
| Medtronic, INC. | $18.93 | 2022 | |
| Antares Pharma, INC. | $18.09 | 2025 | Xyosted |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $16.57 | 2022 | |
| Karl Storz Endoscopy-America | $16.23 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.10 | 2024 | Adstiladrin |
| Urogen Pharma, INC. | $15.93 | 2025 | |
| 180 Medical, INC. | $15.51 | 2022 | |
| Myovant Sciences INC. | $15.03 | 2021 | |
| Novo Nordisk INC | $14.66 | 2024 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $13.90 | 2021 | |
| Allergan, INC. | $12.88 | 2021 | |
| Coloplast Corp | $12.49 | 2019 | |
| Progenics Pharmaceuticals, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darlys Hofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.